What does payment of royalty release fees mean?

Represents one-time cash payments made to buy back or terminate royalty obligations previously sold to investors. This indicates a company's effort to reclaim future revenue rights and improve long-term profitability by reducing ongoing royalty burdens.

BioCryst Pharmaceuticals BCRX Payment Of Royalty Release Fees

Payment Of Royalty Release Fees at other companies

BridgeBio PharmaBBIO

$11.29M+7,742%

Ligand PharmaceuticalsLGND

$0-100%

Ionis PharmaceuticalsIONS

$11.69M-9.3%

AnaptysBio, Inc.ANAB

$0-100%

Viridian Therapeutics, Inc.VRDN

$1.25M—

AnaptysBio, Inc.ANAB

$12.81M-44.3%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:PaymentOfRoyaltyReleaseFees.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's payment of royalty release fees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's payment of royalty release fees?: BioCryst Pharmaceuticals (BCRX) reported payment of royalty release fees of $3.88M in Q4 2025.
What does payment of royalty release fees mean?: Represents one-time cash payments made to buy back or terminate royalty obligations previously sold to investors. This indicates a company's effort to reclaim future revenue rights and improve long-term profitability by reducing ongoing royalty burdens.